Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Blood Cancer Journal
|
June 17, 2025
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
Chandramouli Nagarajan, Wei-Ying Jen, Melissa Ooi, et al.
Hemasphere
|
October 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia
Wei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante, et al.
Blood Advances
|
December 4, 2024
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, et al.
Leukemia
|
April 27, 2026
Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults
Gabriel Aleixo, HeeJin Cheon, Jiayin Zheng, et al.
Research Square
|
February 6, 2026
Development and Validation of the PASS Score: A Simplified Tool to Diagnose Acquired Aplastic Anemia in Adults
Gabriel Aleixo, HeeJin Cheon, Jiayin Zheng, et al.
American Journal of Hematology
|
May 22, 2025
A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Tapan M Kadia, Wei-Ying Jen, Alex Bataller, et al.
Blood Neoplasia
|
September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Cancer
|
August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation
Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood Cancer Journal
|
October 6, 2025
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
Jin Seok Kim, Yang Song, Wei-Ying Jen, et al.
British Journal of Haematology
|
September 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia
Wei-Ying Jen, Guilin Tang, Eitan Kugler, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Blood Cancer Journal
|
June 17, 2025
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
Chandramouli Nagarajan, Wei-Ying Jen, Melissa Ooi, et al.
Hemasphere
|
October 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia
Wei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante, et al.
Blood Advances
|
December 4, 2024
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, et al.
Leukemia
|
April 27, 2026
Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults
Gabriel Aleixo, HeeJin Cheon, Jiayin Zheng, et al.
Research Square
|
February 6, 2026
Development and Validation of the PASS Score: A Simplified Tool to Diagnose Acquired Aplastic Anemia in Adults
Gabriel Aleixo, HeeJin Cheon, Jiayin Zheng, et al.
American Journal of Hematology
|
May 22, 2025
A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Tapan M Kadia, Wei-Ying Jen, Alex Bataller, et al.
Blood Neoplasia
|
September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Cancer
|
August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation
Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood Cancer Journal
|
October 6, 2025
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
Jin Seok Kim, Yang Song, Wei-Ying Jen, et al.
British Journal of Haematology
|
September 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia
Wei-Ying Jen, Guilin Tang, Eitan Kugler, et al.
Page
of 5